AAPS 25th Anniversary. Developing Science. Impacting health.

Lipid-based Delivery for Improving Drug Absorption: Mechanistic Understanding and Practical Approaches 

Goals and Objectives

With the continued increase in the number of poorly soluble and/or permeable compounds, the pharmaceutical industry is being challenged to find appropriate formulation technologies for achieving acceptable bioavailability. Conventional formulation strategies rely on improving BCS II and IV compound solubility by formulating the compound in excipients that promote enhanced in vivo solubilization or by increasing dissolution via reducing particle size. However, gains in bioavailability are often limited due to drug precipitation in-vivo. As a result, more recent approaches have sought to identify (and mitigate) the drivers of in vivo precipitation and also to promote drug supersaturation in the GI fluids following oral administration. The fact that drug transporter and metabolizing systems often play an important role in the bioavailability of drugs has also led to the design of formulations, through the appropriate selection of excipients, to potentially enhance the permeability and absorption of BCS III and IV compounds.

With the push to bring new drugs to market faster, the pharmaceutical industry has made advances in utilizing lipid-based drug delivery systems (LBDDS) to expedite their development. However, many formulation challenges remain. These include designing formulations to maintain drugs in solution, increase permeability, target lymphatic transport, by-pass first pass metabolism, and mitigate food effects. This workshop brings the latest thinking in the design, optimization and characterization of lipid-based formulations as well as the analytical and biopharmaceutical tools necessary for predicting their performance in vivo.

This workshop will be divided into four major areas focusing on the concepts and principles of LBDDS, predictive tools for development and practical approaches to formulating LBDDS for enhancing drug bioavailability and/or permeability.

Who Should Attend

Scientists and managers engaged in all stages of formulation development involving poorly soluble and/or poorly permeable drugs.

Cosponsored by